Waters' New Rapid Screening-DSC Set To Transform Pharmaceutical Testing
Waters Corp. launches TA Instruments RS-DSC for efficient thermal stability testing in biopharma.
Breaking News
Jul 31, 2024
Mrudula Kulkarni

Waters Corp. has launched the TA Instruments Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC) for biopharmaceutical developers worldwide. This advanced high-throughput DSC is engineered for accurate thermal stability testing of high-concentration biological formulations, particularly for antibody drugs and engineered proteins.
Jianqing Bennett, Waters Corporation Senior Vice President
of the TA Instruments Division, remarked, “Demand is increasing for higher
concentration injectable drugs, and biologic developers are looking for
stability testing that is fast and efficient. Our new Rapid Screening-DSC meets
these needs by providing a high-throughput alternative to existing capillary
DSCs and a more reliable and accurate option to differential scanning
fluorescence (DSF) technologies.”
According to the company, the TA Instruments RS-DSC provides
a more convenient and accurate method for evaluating biological drug stability
and quality. It utilizes disposable microfluidic chips (MFCs) with low sample
volumes, allowing up to 24 measurements simultaneously. This innovation
minimizes the need for sample dilution, reduces repetitive instrument cleaning,
and lowers the risk of contamination. Unlike DSF methods, it avoids sensitivity
issues, delivering precise data on high-concentration samples. The RS-DSC also
includes automated software that offers fast, accurate, and comprehensive
insights into a sample's thermodynamic properties.